

1 **A unifying model to explain high nirmatrelvir therapeutic efficacy, low post-exposure**
2 **prophylaxis efficacy, and frequent viral rebound**
3

4
5 **Authors**

6 Shadisadat Esmaeili,^{1*}† Katherine Owens,^{1†} Jessica Wagoner,² Stephen J. Polyak,² Judith M.
7 White,³ Joshua T. Schiffer^{1,2}
8

9 **Affiliations**

10 ¹Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA.

11 ²Department of Medicine, University of Washington; Seattle, WA, USA.

12 ³Department of Cell Biology, University of Virginia; Charlottesville, VA, USA.

13 *Corresponding Author: sesmaeil@fredhutch.org

14 † These authors contributed equally to this work.
15

16 **Abstract**

17 In a pivotal trial, a 5-day course of oral ritonavir-boosted nirmatrelvir, given early during
18 symptomatic infection, decreased hospitalization and death by 89.1% and reduced nasal viral
19 load by 0.87 log relative to placebo in high-risk individuals. Yet, ritonavir-boosted nirmatrelvir
20 failed as post-exposure prophylaxis in a follow-up trial, and frequent viral rebound has been
21 observed in the community. We developed a mathematical model capturing viral-immune
22 dynamics and nirmatrelvir pharmacokinetics that recapitulated viral loads from this and
23 another clinical trial. Our results suggest that nirmatrelvir's *in vivo* potency is significantly
24 lower than *in vitro* assays predict. A maximally potent agent would reduce the viral load by
25 approximately 3.5 logs relative to placebo at 5 days. The model identifies that earlier initiation
26 and shorter treatment duration are key predictors of post-treatment rebound. Extension of early
27 symptomatic treatment to 10 days and post-exposure prophylaxis to 15 days, rather than
28 increasing dose or dosing frequency, is predicted to significantly lower the incidence of viral
29 rebound.
30
31

32 Introduction

33 The SARS-CoV-2 main protease inhibitor nirmatrelvir is a drug plagued by
34 contradictions. In a landmark, randomized, double-blinded, placebo-controlled clinical
35 trial with 1364 analyzed individuals, 300 mg of nirmatrelvir boosted with 100 mg
36 ritonavir was given twice daily for five days to high-risk individuals with SARS-CoV-2
37 infection within 3 days of developing symptoms. Compared to placebo, nirmatrelvir
38 reduced the combined outcome of hospitalization and death by 89%, eliminated death
39 as an outcome, and reduced viral load by 0.87 log after 5 days of treatment(1). This
40 critical result prompted the Food and Drug Administration (FDA) to issue an
41 Emergency Use Authorization(2). The drug became the most widely prescribed
42 antiviral for SARS-CoV-2 in the United States, likely preventing thousands of
43 hospitalizations and many deaths(3). Ritonavir boosted nirmatrelvir was recently
44 licensed by the FDA based on its continued effectiveness and safety(4) and has
45 outperformed other antivirals in terms of hospitalization and viral load reduction(5).

46 However, the use of nirmatrelvir/ritonavir in real-world cohorts has identified viral
47 rebound as a significant issue. Viral rebound occurred in 14.2% of individuals in one
48 large cohort and was usually associated with recrudescence of symptoms, though
49 protection against hospitalization and death appeared to be maintained(6) and remains
50 significant despite high rates of population immunity due to vaccination and prior
51 infection(7). Similar rates of viral rebound were observed between molnupiravir and
52 nirmatrelvir, suggesting the rebound effect is not drug-specific and may pertain to
53 characteristics of SARS-CoV-2 infection and treatment duration(8). This high
54 incidence of viral rebound exceeded the 2.3% rate observed in the proof-of-concept
55 trial, which did not differ from placebo(9).

56 Despite its high efficacy as an early symptomatic therapy for high-risk individuals,
57 nirmatrelvir/ritonavir was not authorized for use as post-exposure prophylaxis (PEP). In
58 a clinical trial of post-exposure prophylaxis, nirmatrelvir/ritonavir showed 32% and
59 37% reductions in symptomatic COVID-19 relative to placebo when given for five or
60 ten days respectively(10). However, neither of these results reached statistical
61 significance. Notably, molnupiravir, another drug that reduced hospitalization when
62 given during early symptomatic infection, also failed as post-exposure prophylaxis(11).
63 Only long-acting monoclonal antibodies have demonstrated efficacy for post-exposure
64 prophylaxis(12–14), but these are no longer active against prevalent circulating
65 strains(15).

66 Early during the COVID-19 pandemic, multiple groups employed mathematical models
67 to predict the outcomes of clinical trials for SARS-CoV-2(16–22). These models all
68 accurately predicted that antiviral therapy that was insufficiently potent or given too
69 late during infection might fail to provide clinical benefit(16–19, 21). Our previous
70 modeling results further suggested that viral rebound may occur and was more likely if
71 a drug was dosed during the pre-symptomatic phase of infection when viral loads are
72 still expanding, as occurs in a post-exposure prophylaxis scenario(23). The proposed
73 mechanism of this effect was that reducing viral load may blunt early immune
74 responses and preserve susceptible cells, allowing viral re-expansion upon cessation of
75 treatment that was of insufficient potency to eliminate all infected cells(24). The model
76 suggested that this phenomenon could theoretically occur during early symptomatic
77 treatment as well. At the time, we downplayed the significance of model-generated
78 rebound as the phenomenon had yet to be demonstrated clinically. However, models fit
79 to rebound data now suggest a similar mechanism of action to explain viral
80 rebound(25).

81 Here we use an updated model for SARS CoV-2 viral kinetics that was first validated
82 against a much larger panel of untreated individuals to precisely simulate the virologic
83 outcomes of two nirmatrelvir/ritonavir trials. We identify that the true *in vivo* potency
84 of nirmatrelvir is approximately significantly less than its *in vitro* potency, such that
85 drug levels are sub-therapeutic during a portion of the dosing interval. Viral rebound is
86 observed in our simulations and is more likely when the drug is dosed early during
87 infection and is not reduced with a higher dose or dosing frequency. Extended-duration
88 treatment is identified as the best strategy to avoid viral rebound.

89

90 Results

91 Viral Dynamic, Pharmacokinetic, and Pharmacodynamic Mathematical models

92 To derive parameters for simulating nasal viral loads in the absence of therapy, we used
93 the mechanistic mathematical model that best recapitulated 1510 SARS-CoV-2
94 infections in a cohort of 2678 SARS-CoV-2 infected individuals from the National
95 Basketball Association cohort (Error! Reference source not found.a) (26). The model is
96 target-cell limited due to a finite number of susceptible cells. An eclipse phase delays
97 viral production by infected cells. In keeping with an early interferon-mediated innate
98 immune response, susceptible cells can become refractory to infection based on the
99 total number of productively infected cells but also revert to susceptible at a constant
100 rate. Infected cells are cleared by cytolysis and early immune response at a constant rate
101 and delayed acquired immunity, which is activated in a time-dependent fashion. We
102 used a mixed-effect population approach implemented in Monolix to estimate model
103 parameters (Fig S1, Table S1).

104 To reproduce levels of nirmatrelvir, we used a two-compartment pharmacokinetic (PK)
105 model (Error! Reference source not found.b). Using Monolix and the mixed-effect
106 population approach, we estimated parameter values by fitting the model to the plasma
107 concentration of healthy subjects. The model closely recapitulated observed drug levels
108 following a single dose of 250mg/100mg of nirmatrelvir/ritonavir (Fig S2, Table S2).
109 The effect of ritonavir as an inhibitor of nirmatrelvir's metabolism is accounted for in
110 the nirmatrelvir's clearance rate in the PK model. We also fit the model to the
111 population level plasma concentrations following a single dose of 250mg/100mg and
112 750mg/100mg showing that the estimated parameters are dose-independent (Table S3).

113 For the pharmacodynamic (PD) model, we assumed the efficacy of the drug follows a
114 Hill equation with respect to the drug concentration. We parameterized the Hill
115 equation using *in vitro* efficacy data collected at different concentrations of nirmatrelvir
116 (details in Materials and Methods, Fig S3, Table S4).

117 To estimate the *in vivo* potency of nirmatrelvir/ritonavir, we fit our model to the viral
118 load drop from the baseline of the control and treatment arms of two randomized,
119 controlled trials: the EPIC-HR trial with 1574 high-risk unvaccinated symptomatic
120 individuals (trial 1)(1) and the PLATCOV trial with 144 low-risk, symptomatic
121 individuals (trial 2) (5). To generate placebo arms for each trial with matched viral
122 variants and vaccine status, we simulated the viral load of 400 randomly selected
123 individuals from the unvaccinated symptomatic subgroup of the NBA cohort (for
124 EPIC-HR) and symptomatic individuals with Omicron infection (for PLATCOV),
125 using their estimated individual viral load parameters. For their symptom onset, we
126 randomly assigned all individuals an incubation period selected from a gamma
127 distribution with parameters associated with each participant's variant reported in the

128 literature (27). The mean viral load drop from the baseline recapitulated the mean
129 change from the baseline of the viral load observed in the control arms of both trials
130 (Error! Reference source not found. **a and 3a**).

131 To simulate the treatment arm, we combined viral dynamics, PK, and PD models. Sets
132 of VL parameters for individuals were again drawn from the NBA cohort following the
133 same criteria as in the control arm to match the cohort characteristics of each trial as
134 closely as possible. The PK and PD parameters for all simulated individuals were
135 randomly drawn from their estimated population distributions. The efficacy of the
136 treatment was calculated from the Hill equation using plasma concentrations of the
137 drug obtained from the PK model. The efficacy of the treatment was used to lower the
138 viral reproduction rate (details in **Materials and Methods, Fig 1**).

139 **Reduction of *in vivo* nirmatrelvir potency relative to *in vitro***

140 To obtain PD parameters of nirmatrelvir, we fit the Hill equation to the *in vitro* efficacy
141 of the drug as a function of its concentration (**Fig S3**). However, the *in vivo* potency of
142 a drug is known to be different from values measured *in vitro* (23, 28, 29). The potency
143 reduction factor (prf) is defined as the ratio between the *in vivo* and *in vitro* IC₅₀. Here
144 the *in vivo* IC₅₀ is the plasma drug concentration required to inhibit viral replication by
145 50%. To identify the *in vivo* potency of nirmatrelvir, we estimated the prf that achieved
146 the best fit between our VL+PKPD model and the average drop in viral load of the
147 treatment arm of the two clinical trials (**Figs 2b and 3b**).

148 To estimate the prf, we simulated the viral load of our virtual cohort of 400 individuals
149 treated with 300 mg of nirmatrelvir twice per day for five days with prf ranging from 1
150 (no reduction in potency) to 120. The treatment start day was randomly selected from a
151 uniform distribution for each simulated individual to be within 3 days of symptom
152 onset. We fit the average change from baseline in simulated viral load data of the
153 treatment arm to the trial data. We then plotted the coefficient of determination, R², of
154 the fit against different prf values (**Figs 2c and 3c**). The best value (prf = 61 for the fit
155 to EPIC-HR and prf=37 when fitting to PLATCOV) was determined by maximizing the
156 R² of the fit. Our model closely recapitulated viral load reduction in the treatment arm
157 of both trials (**Figs 2b and 3b**). We repeated the simulation 10 times and used these
158 replicates to estimate the standard error of the prf. Accordingly, the boxplot in the
159 lower panel of **Figs 2c and 3c** represents the standard error of the prf average value and
160 does not reflect individual variability.

161 The reason for slight differences in estimated prfs between the two trials is unknown.
162 Possible explanations include different sampling methods (nasal swabs in EPIC-HR
163 versus oropharyngeal swabs in PLATCOV) or different participant characteristics
164 (high-risk adults in EPIC-HR versus lower-risk adults without comorbidities in
165 PLATCOV).

166 **Estimates of optimal viral load reduction with an optimal drug**

167 To illustrate the importance of estimating *in vivo* potency of the drug, we compared the
168 PKPD projection and average change in viral load of treatment arms with prf = 1 (no
169 reduction in potency) and prf = 61. With an approximately 61-fold weaker potency, the
170 drug levels dropped below the therapeutic level shortly after each dose and antiviral
171 effect subsided in less than a day after the end of treatment leading to an average
172 efficacy of 82% over the first 5 days of treatment (**Fig 2d, e**). However, the plasma
173 concentration of a perfectly potent drug (prf = 1) remained above therapeutic levels for
174 the duration of the treatment with a 5-day average efficacy of 99.99% and the effect

175 persisted for nearly 10 days (**Fig 2e**). With the perfectly potent drug ($\text{prf} = 1$), with
176 assumed *in vitro* potency level, the same treatment regimen could reduce the viral load
177 by approximately 3.5 logs at day 5 relative to the placebo compared to the 0.87 log
178 reduction reported in the trial (**Fig 2f**).

179 In estimating nirmatrelvir's *in vitro* pharmacodynamic parameters, we assumed only
180 the IC_{50} differs *in vivo*. To confirm the validity of this assumption, we repeated the
181 simulation of the treatment arm of EPIC-HR with different combinations of the potency
182 reduction factor and the Hill coefficient. **Fig S4** shows that the best fit always happened
183 for $\text{prf} \sim 60$ and was independent of the Hill coefficient.

184 The potency reduction factor was more sensitive to certain PK parameters (**Fig S5**),
185 particularly the drug's clearance rate (κ_{CL}). If the drug is assumed to be cleared from
186 the body more rapidly (larger κ_{CL}), then it would need to be more potent (smaller prf) to
187 provide the same effect observed in the clinical trial. However, this did not impact our
188 simulations of different dosing regimens since PK parameters were independent of the
189 dose (**Table S3**). In simulations of different dosing regimens, we therefore use
190 estimated PK parameters and prf distributions from EPIC-HR for all dosing regimens.

191 **Model recapitulation of PLATCOV participant variability**

192 Our model accurately reproduced mean reduction in viral load on multiple post-
193 treatment days in EPIC-HR (**Fig 2b**) and PLATCOV (**Fig 3b**). However, it also
194 predicted variable virologic responses at the individual level, including some instances
195 of viral increase in the days following therapy. To test whether our model reproduced
196 individual level heterogeneity within the trial, we compared simulated and actual
197 distributions of viral load change in the control and treatment arms of the PLATCOV
198 trial. On most post-treatment days, these distributions were not statistically dissimilar
199 (**Fig 3d, e**). Wider distributions of observed versus simulated viral load change were
200 noted on post-randomization days 1 and 2 in the control and days 1 and 4 in the
201 treatment arm (**Fig 3d, e**) perhaps due to noise in viral load data from oral swabs: wide
202 variability was noted between oral samples collected from PLATCOV participants at
203 equivalent timepoints, particularly on day 1 and 2 (**Fig S6**).

204 **Frequent viral rebound on nirmatrelvir**

205 To assess whether our model generated viral rebound, we performed simulations
206 assuming parameter values obtained from fitting the model to data from the EPIC-HR
207 trial (**Fig 2**) and randomly drew individual prf values from the obtained distribution in
208 **Fig 2c**. We performed simulations from the time of infection to 30 days after symptom
209 onset and monitored viral load continually. We defined rebound in the control arm as
210 any case with at least two peaks in the viral load trajectory with minimum heights of 3
211 logs and a second peak higher than its minimum by at least 1 log (**Fig S7a**). We defined
212 rebound in the treatment arm as any instance in which a post-treatment viral load
213 exceeded the viral load at the end of the treatment by 1 log (**Fig S7b**).

214 By this definition, we observed rebound in 21.6% of cases treated with the clinical trial
215 dose and 3.78% of controls (**Fig 4b**). When an equivalent definition of rebound was
216 used as in the trial (1 log increase in viral load 5 days after treatment cessation), the
217 probability of rebound was lower (6.65% if treatment was assumed to begin several
218 days after symptoms), closer to that of the controls, and comparable to that observed in
219 the trial (**Fig S8**).

220 **Limited impact of nirmatrelvir dose or dosing frequency on viral rebound**

221 We next explored different treatment regimens to estimate their impact on lowering
222 viral load and the chance of rebound. We simulated the therapy with 150, 300, 600, and
223 900 mg doses administered twice per day for 5 days, starting within 3 days post
224 symptom onset. A larger dose decreased viral load more significantly and quickly than
225 300 mg twice daily. 900 mg of nirmatrelvir reduced the viral load by a mean of 2 logs
226 on day 2 and a mean of 4 logs on day 5 compared to the control (**Fig 4a**).

227 Individual viral loads were highly variable within each treatment group regardless of
228 dose (**Fig 4a**). This was due to several factors including heterogeneous viral load
229 trajectories (**Fig S1**) and different timing of treatment. Responses to treatment differed
230 substantially according to viral load trajectory and treatment timing as well (**Fig 4c**). In
231 nearly every case, the reduction in viral load was greater during the first 5 days of
232 treatment with higher doses. However, this only impacted viral elimination in certain
233 cases (**Fig 4c,i**). Sometimes viral load equilibrated to similar levels post-treatment
234 regardless of dose (**Fig 4c, ii**), while in other cases, higher doses were associated with
235 rebound (**Fig 4c, iii & iv**). By achieving a lower post-treatment viral load nadir, higher
236 doses resulted in a greater likelihood of viral rebound in our simulations (**Fig 4b**).

237 Increasing frequency of antiviral dosing had nearly equivalent effects to increasing the
238 dose, leading to a more rapid reduction in viral load (**Fig S9a**), heterogeneous effects
239 based on viral load trajectory and timing of treatment (**Fig S9c**), and increased chance
240 of rebound (**Fig S9b**).

241 **Early treatment as a predictor of SARS-CoV-2 rebound**

242 We next simulated therapy with four different timings of treatment: post-exposure
243 prophylaxis (PEP): 0-1 day after infection in the pre-symptomatic phase; early
244 treatment: 0-1 day after symptom onset as often occurs in community settings;
245 intermediate treatment: 1-5 days after symptom onset as in the clinical trial; and late
246 treatment: 5-10 days after symptom onset. In all simulations, the administered dosage
247 was 300mg twice per day for 5 days.

248 Applying treatment as PEP or shortly after symptoms lowered viral load more
249 substantially relative to control than intermediate or late therapy at days 2 and 5 post-
250 treatment, though intermediate and late strategies also significantly lowered viral load
251 relative to control at these timepoints (**Fig 5a**). The boxplots for control groups in each
252 panel in **Fig 5a** show the viral load at different points during the infection to match
253 different timing of the treatment in the treatment arms. However, mean viral load was
254 significantly higher in the PEP group versus the control group 10 days after the start of
255 treatment (**Fig 5a**), due to the high probability of rebound (**Fig 5b, c**) when the virus is
256 at its initial stages of expanding in the body and before the immune response is
257 established in treated individuals.

258 **Prolongation of treatment to reduce the probability of SARS-CoV-2 rebound**

259 Next, we analyzed the impact of treatment duration on viral rebound. We simulated
260 treatment regimens with 300 mg nirmatrelvir given twice per day for 2, 5, 10, 15, and
261 20 days. The treatment was again initiated within 3 days after symptoms appeared. **Fig**
262 **6a** demonstrates the continuous drop in viral load if treatment was maintained until the
263 infection was effectively cleared from the body. The viral load distributions of the
264 treatment arms with 15 and 20 days of treatment on days 2, 5, and 10 were the same as
265 the viral load distribution of the treatment arm with 10 days of treatment duration and,
266 therefore, are not shown. Prolonging treatment duration to 20 days almost completely
267 eliminated viral rebound (**Fig 6b,c**).

268 We next explored the impact of treatment duration on different treatment timing.
269 Prolonging treatment to 15 days for early treatment and 20 days for PEP lowered the
270 viral load close to the limit of detection (2 log) at the end of treatment and significantly
271 lowered the probability of rebound (**Fig 7**).

272 **Differing observed rebound rates resulting from varying timing of sampling and** 273 **definitions**

274 Previous studies have defined rebound using criteria with varying virologic thresholds,
275 timing, and sampling frequency (30). A rebound was sometimes defined when a
276 positive test was observed after a negative test (31). In EPIC-HR, treatment was started
277 within the first 5 days of symptoms (our intermediate treatment group) and rebound
278 was defined as a 0.5 log increase on days 10 and/or 14. By this definition 2.3% of
279 treated cases were classified as rebound (30). The probability of rebound in our
280 simulation with a threshold of 0.5 log measured only on day 5 after the end of the
281 treatment was 8.15% and decreased as thresholds for viral rebound increased (**Fig S8**).
282 This percentage would be even lower if treatment started 3-5 days after symptoms
283 (rather than 1-5 days) because the probability of rebound is very sensitive to the timing
284 of treatment. We hypothesize that in EPIC-HR, participant enrollments were skewed to
285 later during the first 5 day symptom window.

286 In our simulations, we recorded viral load every 0.001 of a day and used a 1 log
287 threshold to identify rebound cases. This would be a more sensitive method to observe
288 rebound and suggests that in trial and real-world cohorts, rebound is likely more
289 common in treated individuals than is detected with less frequent sampling (**Fig S8**).

290 **Immune and viral mechanisms for viral rebound**

291 To understand mechanisms that might explain the increase in rebound in the PEP and
292 early treatment groups, we simulated four treatment arms with the treatment starting on
293 days 1, 4, 7, and 10 after infection. The start day was fixed for all individuals in each
294 arm to limit the added variability introduced by a variable incubation period and timing
295 of treatment relative to symptoms in our previous simulations. The high frequency of
296 rebound in day 1 and day 4 treatment starts was evident from the viral load trajectories
297 after the end of the treatment on days 5 and 9, respectively (**Fig 8a** top row), in many
298 individual trajectories (grey lines) and to a less dramatic extent in mean viral load (blue
299 line). A second peak after the end of the treatment was also seen in the dynamics of
300 infected cells (**Fig 8a** middle row, blue line) and the intensity of the innate immune
301 response (the rate of production of refractory cells) (**Fig 8a** bottom row).

302 Applying the treatment earlier during infection (day 1 and day 4 in the case of our
303 simulations) lowered the viral load as well as the populations of infected and refractory
304 cells, preserving susceptible cells. The ratio of susceptible to refractory cells in the two
305 groups with earlier treatment starting points (day 1 and day 4) was significantly higher
306 at the end of the treatment than in the control group at equivalent time points (**Fig 8b**).
307 At each time point, innate immune responses were significantly diminished in treated
308 individuals versus controls due to fewer infected cells (**Fig 8c**). Overall, a weaker
309 innate immune response, higher availability of susceptible cells and persistence of
310 infected cells after 5 days of treatment, allowed viral rebound after treatment cessation.

311 In a parallel manuscript, we subset shedding groups in the NBA cohort according to
312 shedding kinetics using k-means clustering. The groups were ordered based on the area
313 under their viral load curve (AUC) with group 1 having the smallest AUC and group 6
314 the largest (**Fig S10a**). We simulated treatment with different treatment start days using

315 these 6 groups and identified the highest rebound probability in the earlier treatment
316 groups with the larger AUC (groups 5 and 6) and longer time to peak viral load (groups
317 3, 5, and 6) prior to antiviral therapy (**Fig S10b, c**). This indicates that viral rebound
318 may be more likely in individuals who were destined for more severe infections had
319 they not received therapy.

320

321 Discussion

322 We previously demonstrated for herpes simplex virus-2(32), HIV(33), Ebola virus(28),
323 and SARS-CoV-2(23), that it is vital to consider the timing and intensity of the immune
324 response to accurately simulate clinical trials of antiviral agents. If a direct-acting
325 antiviral therapy is given too late during infection, then efficacy is often low because
326 the disease is driven by excess inflammation and cytokine storm. On the other hand,
327 concurrent immune pressure can provide critical assistance for antiviral agents to
328 eliminate viral replication, as confirmed in recent studies(7). Accordingly, our previous
329 modeling suggested that extremely early treatment of pre-symptomatic SARS-CoV-2
330 as occurs with PEP requires higher drug potency than treatment during early
331 symptomatic infection because innate immunity is activated to a greater extent at this
332 slightly later stage of infection and fewer susceptible cells remain(23). It is increasingly
333 clear that the potency and duration of antiviral therapy required to achieve clinical
334 benefit depends strongly on the stage of infection and the ongoing intensity of the
335 immune response.

336 Our prior work also demonstrated that *in vitro* antiviral drug potency measured in
337 relevant cell culture lines often overestimates *in vivo* potency in humans(28, 29, 34).
338 Specifically, the plasma drug level required to achieve 50% inhibition of cellular
339 infections *in vivo* is higher than the level required to inhibit infection *in vitro*. The
340 discrepancy between *in vitro* and *in vivo* potency can only be assessed by fitting viral
341 dynamic / PKPD mathematical models to viral load data from clinical trials, as we have
342 done here. Traditional PKPD models, which do not account for the dynamics of an
343 immune response on observed viral loads, are not sufficient to estimate *in vivo* potency.
344 Because *in vivo* potency reduction varies from 2 to 100 depending on the infection,
345 antiviral agents(28, 32, 34), and population *in vivo* IC₅₀ must be assessed separately in
346 each case.

347 Here by precisely fitting a combined viral-immune dynamic / PKPD model to viral load
348 data from placebo and treatment groups in a randomized clinical trial as well as an
349 open-label clinical trial of nirmatrelvir/ritonavir, we merge these two key concepts. We
350 first identify that nirmatrelvir potency is reduced 60-70 fold *in vivo* relative to *in vitro*
351 in the high-risk population and 30-40 fold in the healthy population. The difference
352 between the estimated *in vivo* potency in these two populations can be explained by the
353 differences in the demographics and sampling methods in the two trials. The
354 mechanistic reasons for this reduction cannot be determined by the model but may
355 include increased *in vivo* protein binding(35), inhibition of drug delivery from plasma to
356 sites of infection, or differences in cellular uptake and drug metabolism *in vivo*(36).
357 Nevertheless, our estimated *in vivo* IC₅₀ provides a benchmark plasma level to target in
358 future trials. The PK model also demonstrates that the drug's relatively short half-life
359 ($t_{1/2}$) allows it to dip to subtherapeutic levels even when dosed twice daily.

360 Our model also develops a viable hypothesis for why nirmatrelvir is highly effective
361 when given during early symptomatic infection but less so when given as post-exposure
362 prophylaxis. By preventing a high peak viral load approximately 3-5 days after
363 infection, therapy preserves susceptible cells and blunts the immediate, likely innate

364 immune response to SARS-CoV-2, while not completely eliminating infected cells. If
365 the virus is not eliminated by an early acquired response along with antiviral pressure,
366 it rebounds to a peak level that is sometimes comparable to the initial peak. We
367 hypothesize that viral rebound occurs more frequently in community settings relative to
368 the clinical trial. Infected individuals in the community are often prescribed the drug
369 very early after symptom development, whereas in the trial, there was a natural 1 to 2-
370 day delay based on the enrollment and consent process. Surprisingly, this short delay
371 may have limited rebound while not affecting the primary endpoints of the trial, a
372 finding supported by recent clinical studies(37), which nevertheless still suggest a clear
373 benefit for earlier treatment in terms of preventing hospitalization in high-risk
374 individuals(7). Notably, antiviral therapy is not a risk factor for rebound in our model or
375 in clinical cohorts of individuals treated late during infection(38). High viral load
376 shedding is also a risk factor for rebound in our model as has been suggested in other
377 studies (39).

378 Our model identifies optimal conditions for viral rebound, which counterintuitively
379 include early treatment during pre-symptomatic infection, which can be exacerbated by
380 higher or more frequent dosing. Both mechanisms occur by suppressing the amount of
381 infection and preserving susceptible cells, limiting the development of refractory cells,
382 and dampening the intensity of the early immune response. The best method to prevent
383 viral rebound is prolonging treatment, with a longer course needed for PEP. This
384 finding is consistent with trials of long-acting monoclonal antibodies, which
385 demonstrated efficacy as post-exposure prophylaxis(12–14).

386 Because the model is validated precisely against mean viral load reduction from two
387 trials as well as individual viral kinetic distributions within each arm of one trial, it can
388 be used as a tool to test various treatment strategies for future trials with the ability to
389 vary therapeutic goals, timing of treatment, dose, dosing interval, and duration of
390 therapy. Our prior PD modeling also allows testing of potentially synergistic
391 combination agents and consideration of special hosts such as immunocompromised
392 individuals with persistent infection who may be at risk of developing drug
393 resistance(28, 40). We believe our approach provides a template for optimizing future
394 trial designs with nirmatrelvir and other therapies.

395 Our model has several limitations. First, nasal or oropharyngeal viral load may not be a
396 perfect surrogate of disease activity. On the one hand, viral load reduction has been
397 correlated with beneficial clinical outcomes for nirmatrelvir(1), molnupiravir(41), and
398 monoclonal antibodies(42). A recent review shows that viral load reduction is a
399 reasonably good surrogate endpoint(42). Moreover, the viral rebound appears to track
400 very closely with the symptomatic rebound in multiple case series(30). Yet, early
401 remdesivir treatment provided a profound reduction in hospitalization while not
402 impacting nasal viral load, albeit 5 days after completion of therapy (43). Data from
403 non-human primates suggests that the drug has a specific effect on viral loads in the
404 lungs that is not observed in upper airways, a finding that we were also able to capture
405 with models(23). Overall, there is a strong suggestion from early treatment trials that a
406 reduction in nasal viral loads beyond that observed in placebo-treated individuals is
407 associated with substantial clinical benefit(1).

408 Another limitation is that the model does not account for drug resistance. While there
409 has been limited evidence of de novo resistance during nirmatrelvir therapy, serial
410 passage of virus suggests a relatively low barrier, and some viral rebound could, in
411 theory, be with resistant variants. Studies to date suggest very little mutational change
412 between the infecting and rebounding virus(44–47).

413 Our model does not capture immunity in literal terms. For instance, we do not
414 distinguish innate interferon, antibody, and T-cell responses, as these have not been
415 measured in sufficient longitudinal detail to precisely ascribe viral clearance to different
416 components of the immune response. We structured the model for the early response to
417 roughly map to innate responses, as the model term capturing the progression of
418 susceptible cells to a refractory state diminishes with decreases in viral load and
419 assumes no immune memory. The late immune response in our model has memory,
420 leads to rapid elimination of the virus, and is likely to represent acquired immunity.
421 While a more accurate model would discriminate different arms of the immune
422 responses and fit to immune data, ours sufficiently captures the timing and intensity of
423 immune responses for accurate clinical trial simulation.

424 Finally, it is our opinion that models lacking a spatial component cannot capture the
425 full dynamics of target cell limitation, which is influenced by the packing structure of
426 cells, dynamics of viral diffusion, and infection within multiple concurrent micro-
427 environments(32). For these reasons, ordinary differential equations may misclassify
428 the relative impact of target cell limitation and innate immune responses in the period
429 surrounding peak viral load. However, our differential equation approach provides
430 accurate output for clinical trial simulation.

431 In conclusion, our model identifies viable mechanistic underpinnings of the high
432 efficacy of nirmatrelvir therapy for early symptomatic SARS-CoV-2 infection, lower
433 efficacy for PEP, and high incidence of viral rebound in a real-world setting. The model
434 can also be used to assess different treatment strategies and suggests prolonging therapy
435 is the optimal method to avoid rebound and maintain potent early antiviral suppression.
436

437 **Materials and Methods**

438 **Study Design**

439 We developed a viral dynamics model recapitulating the viral load data collected from
440 symptomatic individuals in the NBA (National Basketball Association) cohort(48). We
441 used a two-compartment model to reproduce the PK data of nirmatrelvir plus
442 ritonavir(2). For the simulation, we constructed a virtual cohort by randomly selecting
443 400 individuals from the NBA cohort, trying to match the trial populations regarding
444 the vaccine status and history of infection, and assigning individual PK and PD
445 parameters randomly drawn from their respective inferred distributions. We fit the
446 combined viral dynamics and PK/PD model to the average change in viral load from
447 the baseline of the control and treatment arms of the two previously published
448 nirmatrelvir/ritonavir clinical trials (1, 5). By fitting our model to the control arms, we
449 validated our viral dynamics model and how well the viral dynamics of our virtual
450 cohort represent the trial control arms. We used the fit to the treatment arms to estimate
451 the potency reduction factor (prf) by maximizing the R^2 of the fit. With the estimated
452 prf and *in vivo* IC_{50} of the drug, we explored different treatment regimens by changing
453 dose, dosing frequency, treatment duration, and treatment timing, to find the best
454 strategy to minimize the probability of rebound.

455 **Viral load data**

456 We used data from the symptomatic subpopulation of the NBA cohort published by
457 Hay et al(48). The NBA cohort dataset consists of 2875 documented SARS-CoV-2
458 infections in 2678 people detected through frequent PCR testing regardless of
459 symptoms. 1510 infections in 1440 individuals had at least 4 positive quantitative

460 samples. We used the viral load data from the 1510 infections to estimate the viral load
461 parameters.

462 **Clinical trial data**

463 We used viral load data from two nirmatrelvir/ritonavir clinical trials. EPIC-HR by
464 Hammond et al. (1) included 682 and 697 symptomatic high-risk individuals in the
465 control and treatment arms, respectively. We obtained the average change in viral load
466 data of the control and treatment arms by digitizing Figure 3A of the manuscript(1).
467 Nasal viral load was measured on days 0, 3, 5, 10, and 14 after the treatment start day
468 and adjusted by the baseline viral load. PLATCOV by Schilling et al. (5) is an open-
469 label, randomized, controlled adaptive trial with 85 and 59 symptomatic, young,
470 healthy individuals in the control and nirmatrelvir treatment arms, respectively. The
471 viral load samples from each participant were collected on days 0 through 7 and day 14
472 after treatment start day. We used the individual viral load data made available by the
473 authors. From PLATCOV, we averaged over the two oral samples collected from each
474 individual and calculated viral load drop from baseline. In both trials, the study
475 participants were treated with 300mg/100mg nirmatrelvir/ritonavir within three days
476 (EPIC-HR) or four days (PLATCOV) of symptoms onset. The treatment was
477 administered twice per day, for five days. We used EPIC-HR's lower limit of detection
478 (2 log imputed as 1 log) in our simulations. However, when fitting to PLATCOV, we
479 used the maximum LOD reported in the published data.

480 **PK data**

481 PK data of nirmatrelvir (PF-07321332) with ritonavir was obtained by digitizing Figure
482 4 of the drug's Emergency Use Authorization document(2). The data is from a phase I
483 randomized trial by Singh et al.(49) where eight participants (4 fed, 4 not fed) took a
484 single dose of 250mg/100mg nirmatrelvir/ritonavir. The plasma concentrations of the
485 drug in participants were recorded in the next 48 hours after dosing.

486 **PD data**

487 The data on drug efficacy comes from five replicates per condition, pooled from 2
488 independent technical experimental repeats (one experiment with triplicate conditions,
489 one experiment in duplicate conditions) performed at the University of Washington.
490 The efficacy of Nirmatrelvir in the presence of CP-100356 (an efflux inhibitor (50))
491 was measured against the delta variant of SARS-CoV2 in Calu-3 cells. The efflux
492 inhibitor ensures consistent, adequate intracellular levels of drug. Briefly, Calu 3 cells
493 human lung epithelial were treated with varying concentrations of nirmatrelvir in the
494 presence of 2uM CP-100356 prior to infection with SARS-CoV-2 (delta isolate) at a
495 multiplicity of infection of 0.01. Antiviral efficacy and cell viability (of non-infected
496 cells treated with drugs) were assessed as described(51).

497 **Viral dynamics model**

498 We used our model of SARS-CoV-2 dynamics(26) to model the viral load dynamics of
499 symptomatic individuals with SARS-CoV-2 infection. Our model assumes that
500 susceptible cells (S) are infected at rate βVS by SARS-CoV-2 virions. The infected
501 cells go through a non-productive eclipse phase (I_E) before producing viruses and
502 transition to becoming productively infected (I_P) at rate κI_E . When encountering
503 productively infected cells, the susceptible cells become refractory to infection (R) at
504 the rate $\phi I_P S$. Refractory cells revert to a susceptible state at rate ρR . The productively
505 infected cells are cleared at rate δI representing cytolysis and the innate immune
506 response that lacks memory and is proportional to the amount of ongoing infection. If

507 the infection persists longer than τ , then cytotoxic acquired immunity gets involved,
 508 which is represented in our model by the rate mI_P . Finally, free virions are cleared at
 509 the rate γ . Of note, this model, previously proposed by Ke et al. (52), was selected
 510 against other models in(26) based on superior fit to data and parsimony. The model
 511 written as a set of differential equations has the form,

512
 513

$$514 \quad \frac{dS}{dt} = -\beta SV - \phi I_P S + \rho R \quad (1a)$$

$$515 \quad \frac{dR}{dt} = \phi I_P S - \rho R \quad (1b)$$

$$516 \quad \frac{dI_E}{dt} = \beta SV - \kappa I_E \quad (1c)$$

$$517 \quad \frac{dI_P}{dt} = \kappa I_E - \delta I_P - m(t)I_P \quad (1d)$$

$$518 \quad \frac{dV}{dt} = \pi I_P - \gamma V \quad (1e)$$

$$519 \quad \text{where } \begin{cases} m(t) = 0 & t < \tau \\ m(t) = m & t \geq \tau \end{cases} \quad (1f)$$

520

521 To estimate parameter values, we fit the model to viral load data from the NBA cohort
 522 using a mixed-effect population approach implemented in Monolix.

523 We start the simulations with 10^7 susceptible cells. The initial value of the refractory
 524 cells is assumed to be zero since the interferon signaling is not active prior to infection.
 525 We further assume there are no infected cells (eclipse or productive) at the beginning of
 526 the infection. We fix the level of inoculum (V_0) at 97 copies/ml for each individual.

527 To resolve identifiability issues, we fixed two parameter values, setting the inverse of
 528 the eclipse phase duration to $\kappa = 4$, the rate of clearance of virions to $\gamma = 15(26)$.

529 PK model

530 We used a two-compartmental PK model which includes the amount of drug in the GI
 531 tract (A_{GI}), the plasma compartment (A_p), and the lung (A_L). The drug is administered
 532 orally, passes through the GI tract and gets absorbed into the blood at the rate κ_a . The
 533 drug then transfers from the blood into the peripheral compartment (or the lung) at the
 534 rate κ_{PL} . The metabolized drug transfers back into the plasma at the rate κ_{LP} from
 535 where it clears from the body at the rate κ_{CL} . The model in the form of ordinary
 536 differential equations is written as,

$$537 \quad \frac{dA_{GI}}{dt} = -\kappa_a A_{GI} \quad (2a)$$

$$538 \quad \frac{dA_p}{dt} = \kappa_a A_{GI} + \kappa_{LP} A_L - (\kappa_{CL} + \kappa_{PL}) A_p \quad (2b)$$

$$539 \quad \frac{dA_L}{dt} = \kappa_{PL} A_p - \kappa_{LP} A_L \quad (2c)$$

540

541 We used Monolix and a mixed-effect population approach to estimate the parameters
 542 and their standard deviations. With the initial condition of ($A_{GI} = Dose$, $A_p = 0$,

543 $A_L = 0$); we fit $C_p = \frac{A_p}{Vol}$ to the plasma concentration data where Vol is the estimated
544 plasma volume.

545 **PD model**

546 For the pharmacodynamics model we used Hill equation, $\epsilon(t) = \frac{E_{max}C(t)^n}{C(t)^n + IC_{50}^n}$, where $C(t)$
547 is the drug's concentration in plasma, E_{max} is the maximum efficacy, n is the hill
548 coefficient, and IC_{50} is the drug concentration in plasma required to provide 50%
549 efficacy. We used least-squared fitting to obtain the three parameters and their standard
550 deviations. The average drug efficacy is measured using,

$$551 \quad E_{ave} = \frac{1}{t_{start} - t_{end}} \int_{t_{start}}^{t_{end}} \epsilon(t) dt \quad (3)$$

552 Where t_{start} and t_{end} are the treatment start day and end day respectively.

553

554 **Combined PKPD and VL models**

555 The plasma concentration of nirmatrelvir obtained from the PK model is used in the PD
556 model to obtain time-dependent efficacy. $\epsilon(t)$, then, is used to reduce viral production
557 rate, π , with the factor of $(1 - \epsilon(t))$. Equation 1e is written as,

$$558 \quad \frac{dV}{dt} = (1 - \epsilon(t))\pi I_p - \gamma V \quad (4)$$

559

560 **Construction of a virtual cohort**

561 To generate a cohort for our simulated clinical trials, we randomly selected 400
562 individuals (for each arm of the simulated trial) from the unvaccinated symptomatic
563 subpopulation of the NBA cohort and used their individual viral load parameters
564 estimated by fitting our viral dynamics model to the data. For their incubation period,
565 we drew randomly from gamma distributions with parameters associated with their
566 variants of concern (27). PK parameters of each simulated individual were randomly
567 drawn from the lognormal distributions with their estimated mean and standard
568 deviation inferred from PK data. The PD parameters were also randomly drawn from
569 the normal distribution with the estimated mean and standard deviation. The standard
570 deviation of the PD parameters represents the accuracy of the assays and not the
571 individual variability. The individual potency reduction factors were also drawn from a
572 normal distribution with mean and standard deviation obtained from fitting ten
573 simulations to the treatment arm of trial 1.

574 **Potency reduction factor (prf)**

575 The potency reduction factor (prf) is defined as,

$$576 \quad prf = \frac{IC_{50, in vivo}}{IC_{50, in vitro}} \quad (5)$$

577

578 We estimated the prf by maximizing R^2 when fitting the change in viral load of the
579 treatment arm of our simulation to the data from the treatment arm of the clinical trial.

580 **Measuring rebound probability**

581 A viral load rebound in the treatment arm was defined when the viral load at any time
582 after treatment ended exceeded the viral load at the end of the treatment by 1 log. In the
583 control group, viral rebound was defined in patients who had at least two peaks with
584 maximum height of 1000 copies/ml in their viral load trajectories and the second peak
585 was 1log higher than its local minimum (**Fig S7**).

587 References

- 588
- 589 1. J. Hammond, H. Leister-Tebbe, A. Gardner, P. Abreu, W. Bao, W. Wisemandle, M. Baniecki, V. M. ,
590 Hendrick, B. Damle, A. Simon-Campos, R. Pypstra, J. M. Rusnak, Oral Nirmatrelvir for High-Risk,
591 Nonhospitalized Adults with Covid-19. *N Engl J Med* **386**, 1397–1408 (2022).
 - 592 2. Emergency Use Authorization for Paxlovid (nirmatrelvir tablets co-packaged with ritonavir tablets) Center for
593 Drug Evaluation and Research (CDER) Review. *Food and Drug Administration* (2021) (available at
594 <https://www.fda.gov/media/155194/download>).
 - 595 3. M. Khunte, S. Kumar, J. A. Salomon, A. Bilinski, Projected COVID-19 Mortality Reduction From Paxlovid
596 Rollout. *JAMA Health Forum* **4**, E230046 (2023).
 - 597 4. FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults. *Food and Drug Administration*
598 (available at [https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-](https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults)
599 [covid-19-adults](https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults)).
 - 600 5. W. H. K. Schilling, P. Jittamala, J. A. Watson, S. Boyd, V. Luvira, T. Siripoon, T. Ngamprasertchai, E. M.
601 Batty, C. Cruz, J. J. Callery, S. Singh, M. Saroj, V. Kruabkontho, T. Ngernseng, N. Tanglakmankhong, J.
602 Tubprasert, M. Y. Abdad, W. Madmanee, J. Kouhathong, K. Suwannasin, W. Pagornrat, N. Piaraksa, P.
603 Hanboonkunupakarn, B. Hanboonkunupakarn, K. Poovorawan, M. Potaporn, A. Srisubat, B. Loharjun, W. R. J.
604 Taylor, V. Chotivanich, K. Chotivanich, M. Imwong, S. Pukrittayakamee, A. M. Dondorp, N. P. J. Day, M. M.
605 Teixeira, W. Piyaphanee, W. Phumratanaprapin, N. J. White, N. J. White, W. H. Schilling, W. Phumratanaprapin,
606 V. Luvira, J. J. Callery, N. P. Day, S. Pukrittayakamee, S. Boyd, C. Cruz, A. M. Dondorp, W. R. Taylor, J. A.
607 Watson, W. Piyaphanee, K. Poovorawan, T. Ngamprasertchai, T. Siripoon, B. Hanboonkunupakarn, K.
608 Chotivanich, P. Jittamala, M. Imwong, J. Thaipadungpanit, M. Ekkapongpisit, V. Kruabkontho, T. Ngernseng, J.
609 Tubprasert, M. Y. Abdad, E. M. Batty, S. Singh, V. Chotivanich, W. Ruksakul, C. Sangketchon, P.
610 Hanboonkunupakarn, S. Sookprome, M. Teixeira, P. J. Almeida, R. S. Aguiar, F. Santos, E. Ashley, M.
611 Vongsouvath, K. Phommason, A. Dubot-Pères, S. Vidhamaly, A. Chingsanoon, S. Bisayher, D. Chommanam, T.
612 J. Evans, V. Vidhamaly, L. Boutthasavong, M. Mayxay, M. Potaporn, A. Srisubat, B. Loharjun, Antiviral efficacy
613 of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19
614 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial. *Lancet Infect Dis* **0** (2023),
615 doi:10.1016/S1473-3099(23)00493-0.
 - 616 6. J. A. Pandit, J. M. Radin, D. C. Chiang, E. G. Spencer, J. B. Pawelek, M. Diwan, L. Roumani, M. J. Mina, The
617 Coronavirus Disease 2019 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound
618 Differences in Participants Treated With Nirmatrelvir Plus Ritonavir Versus Untreated Controls. *Clinical*
619 *Infectious Diseases* **77**, 25–31 (2023).
 - 620 7. C. K. H. Wong, J. J. Lau, I. C. H. Au, K. T. K. Lau, I. F. N. Hung, M. Peiris, G. M. Leung, J. T. Wu, Optimal
621 timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation. *Nat*
622 *Commun* **14** (2023), doi:10.1038/s41467-023-43706-0.
 - 623 8. L. Wang, N. A. Berger, P. B. Davis, D. C. Kaelber, N. D. Volkow, R. Xu, COVID-19 rebound after Paxlovid
624 and Molnupiravir during January-June 2022. *medRxiv* (2022), doi:10.1101/2022.06.21.22276724.
 - 625 9. A. S. Anderson, P. Caubel, J. M. Rusnak, Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19. *New*
626 *England Journal of Medicine* **387**, 1047–1049 (2022).
 - 627 10. Pfizer Shares Top-Line Results from Phase 2/3 EPIC-PEP Study of PAXLOVID™ for Post-Exposure
628 Prophylactic Use. *Pfizer* (available at [https://www.pfizer.com/news/press-release/press-release-detail/pfizer-](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-top-line-results-phase-23-epic-pep-study)
629 [shares-top-line-results-phase-23-epic-pep-study](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-top-line-results-phase-23-epic-pep-study)).
 - 630 11. Merck Provides Update on Phase 3 MOVE-AHEAD Trial Evaluating LAGEVRIO™ (molnupiravir) for Post-
631 exposure Prophylaxis for Prevention of COVID-19 - Merck.com (available at
632 [https://www.merck.com/news/merck-provides-update-on-phase-3-move-ahead-trial-evaluating-lagevr-io-](https://www.merck.com/news/merck-provides-update-on-phase-3-move-ahead-trial-evaluating-lagevr-io-molnupiravir-for-post-exposure-prophylaxis-for-prevention-of-covid-19/)
633 [molnupiravir-for-post-exposure-prophylaxis-for-prevention-of-covid-19/](https://www.merck.com/news/merck-provides-update-on-phase-3-move-ahead-trial-evaluating-lagevr-io-molnupiravir-for-post-exposure-prophylaxis-for-prevention-of-covid-19/)).
 - 634 12. C. Hirsch, Y. S. Park, V. Piechotta, K. L. Chai, L. J. Estcourt, I. Monsef, S. Salomon, E. M. Wood, C. So-
635 Osman, Z. McQuilten, C. D. Spinner, J. J. Malin, M. Stegemann, N. Skoetz, N. Kreuzberger, SARS-CoV-2-
636 neutralising monoclonal antibodies to prevent COVID-19. *Cochrane Database Syst Rev*, Art. No.: CD014945
637 (2022).
 - 638 13. M. P. O'Brien, E. Forleo-Neto, N. Sarkar, F. Isa, P. Hou, K. C. Chan, B. J. Musser, K. J. Bar, R. V. Barnabas,
639 D. H. Barouch, M. S. Cohen, C. B. Hurt, D. R. Burwen, M. A. Marovich, E. R. Brown, I. Heirman, J. D. Davis, K.

- 640 C. Turner, D. Ramesh, A. Mahmood, A. T. Hooper, J. D. Hamilton, Y. Kim, L. A. Purcell, A. Baum, C. A.
641 Kyratsous, J. Krainson, R. Perez-Perez, R. Mohseni, B. Kowal, A. T. Dicioccio, G. P. Geba, N. Stahl, L. Lipsich,
642 N. Braunstein, G. Herman, G. D. Yancopoulos, D. M. Weinreich, Effect of Subcutaneous Casirivimab and
643 Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early
644 Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. *JAMA* **327**, 432–441 (2022).
- 645 14. M. P. O'Brien, E. Forleo-Neto, B. J. Musser, F. Isa, K.-C. Chan, N. Sarkar, K. J. Bar, R. V. Barnabas, D. H.
646 Barouch, M. S. Cohen, C. B. Hurt, D. R. Burwen, M. A. Marovich, P. Hou, I. Heirman, J. D. Davis, K. C. Turner,
647 D. Ramesh, A. Mahmood, A. T. Hooper, J. D. Hamilton, Y. Kim, L. A. Purcell, A. Baum, C. A. Kyratsous, J.
648 Krainson, R. Perez-Perez, R. Mohseni, B. Kowal, A. T. DiCioccio, N. Stahl, L. Lipsich, N. Braunstein, G.
649 Herman, G. D. Yancopoulos, D. M. Weinreich, Subcutaneous REGEN-COV Antibody Combination to Prevent
650 Covid-19. *N Engl J Med* **385**, 1184–1195 (2021).
- 651 15. G. A. Herman, M. P. O'Brien, E. Forleo-Neto, N. Sarkar, F. Isa, P. Hou, K. C. Chan, K. J. Bar, R. V.
652 Barnabas, D. H. Barouch, M. S. Cohen, C. B. Hurt, D. R. Burwen, M. A. Marovich, B. J. Musser, J. D. Davis, K.
653 C. Turner, A. Mahmood, A. T. Hooper, J. D. Hamilton, J. Parrino, D. Subramaniam, A. Baum, C. A. Kyratsous,
654 A. T. DiCioccio, N. Stahl, N. Braunstein, G. D. Yancopoulos, D. M. Weinreich, A. Chani, A. Adepoju, A.
655 Mortagy, A. Dupljak, A. Brown, A. Froment, A. Hooper, A. Margiotta, A. Bombardier, A. Islam, A. Smith, A.
656 Dhillon, A. McMillian, A. Breazna, A. Aslam, B. Carpentino, B. Kowal, B. Siliverstein, B. Horel, B. Zhu, B.
657 Musser, B. Bush, B. Head, B. Snow, B. Zhu, C. Debray, C. Phillips, C. Simiele, C. Lee, C. Nienstedt, C. Trbovic,
658 C. (Kuo C. Chan, C. Elliott, C. Fish, C. Ni, C. Polidori, C. Enciso, C. Caira, C. Powell, C. A. Kyratsous, C. Baum,
659 C. McDonald, C. Leigh, C. Pan, D. Wolken, D. Manganello, D. Liu, D. Stein, D. M. Weinreich, D. Hassan, D.
660 Gulabani, D. Fix, D. Leonard, D. Sarda, D. Bonhomme, D. Kennedy, D. Darcy, D. Barron, D. Hughes, D. Rofail,
661 D. Kaur, D. Ramesh, D. Bianco, D. Cohen, E. Jean-Baptiste, E. Bukhari, E. Doyle, E. Bucknam, E. Labriola-
662 Tomkins, E. Nanna, E. Huffman O'Keefe, E. Gasparino, E. Fung, F. Y. To, G. Herman, G. D. Yancopoulos, G.
663 Bellingham, G. Sumner, G. Moggan, G. Power, H. Zeng, H. Mariveles, H. Gonzalez, H. Kang, H. Noor, I. Minns,
664 I. Heirman, I. Peszek, J. Donohue, J. Rusconi, J. Austin, J. Yo, J. McDonnell, J. D. Hamilton, J. Boarder, J. Wei,
665 J. Yu, J. Malia, J. Tucciarone, J. Tyler-Gale, J. D. Davis, J. Strein, J. Cohen, J. Meyer, J. Ursino, J. Im, J.
666 Tramaglino, J. Wolken, K. Potter, K. Scacalossi, K. Naidu, K. Browning, K. Rutkowski, K. Yau, K. Woloshin, K.
667 Lewis-Amezcu, K. Turner, K. Dornheim, K. Chiu, K. Mohan, K. McGuire, K. Macci, K. Ringleben, K.
668 Mohammadi, K. Foster, L. Knighton, L. Lipsich, L. Darling, L. Boersma, L. Cowen, L. Hersh, L. Jackson, L.
669 Purcell, L. Sherpinsky, L. Lai, L. Faria, L. Geissler, L. Boppert, L. Fiske, M. Dickens, M. Mancini, M. C. Leigh,
670 M. P. O'Brien, M. Batchelder, M. Klinger, M. Partridge, M. Tarabocchia, M. Wong, M. Rodriguez, M. Albizem,
671 M. O'Byrne, N. Deitz, N. Memblatt, N. Shah, N. Kumar, O. Herrera, O. Adedoyin, O. Yellin, P. Snodgrass, P.
672 Floody, P. D' Ambrosio, P. (Xiaobang) Gao, P. Hearld, Q. Li, R. Kitchenoff, R. Ali, R. Iyer, R. Chava, R. Alaj, R.
673 Pedraza, R. Hamlin, R. Hosain, R. Gorawala, R. White, R. Yu, R. Fogarty, S. B. Dass, S. Bollini, S. Ganguly, S.
674 DeCicco, S. Patel, S. Cassimaty, S. Somersan-Karakaya, S. McCarthy, S. Henkel, S. Ali, S. Geila Shapiro, S.
675 Kim, S. Nossoughi, S. Bisulco, S. Elkin, S. Long, S. Sivapalasingam, S. Irvin, S. Wilt, T. Min, T. Constant, T.
676 Devins, T. DiCioccio, T. Norton, T. Bernardo, T. C. Chuang, V. (Jianguo) Wei, V. Nuce, V. Battini, W. Caldwell,
677 X. Gao, X. Chen, Y. Tian, Y. Khan, Y. Zhao, Y. Kim, B. Dye, C. B. Hurt, D. R. Burwen, D. Burns, E. Brown, K.
678 J. Bar, M. Marovich, M. Clement, M. S. Cohen, N. Sista, R. V. Barnabas, S. Zwierski, Efficacy and safety of a
679 single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a
680 randomised, double-blind, placebo-controlled trial. *Lancet Infect Dis* **22**, 1444–1454 (2022).
- 681 16. K. Su, K. Ejima, Shoya Iwanami, Y. Fujita, H. Ohashi, Y. Koizumi, Y. Asai, S. Nakaoka, K. Watashi, K.
682 Aihara, R. N. Thompson Id, R. Ke, A. S. Perelson, Shingo Iwami, A quantitative model used to compare within-
683 host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment
684 of SARS-CoV-2. *PLoS Biol* **19**, e3001128 (2021).
- 685 17. S. Wang, Y. Pan, Q. Wang, H. Miao, A. N. Brown, L. Rong, Modeling the viral dynamics of SARS-CoV-2
686 infection. *Math Biosci* **328**, 108438 (2020).
- 687 18. A. S. Perelson, R. Ke, Mechanistic Modeling of SARS-CoV-2 and Other Infectious Diseases and the Effects
688 of Therapeutics. *Clin Pharmacol Ther* **109**, 829–840 (2021).
- 689 19. S. Sanche, T. Cassidy, P. Chu, A. S. Perelson, R. M. Ribeiro, R. Ke, A simple model of COVID-19 explains
690 disease severity and the effect of treatments. *Sci Rep* **12**, 14210 (2022).
- 691 20. P. Czuppon, F. Débarre, A. Gonçalves, O. Tenaillon, A. S. Perelson, J. Guedj, F. Blanquart, Success of
692 prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific
693 mechanisms of action. *PLoS Comput Biol* **17**, e1008752 (2021).
- 694 21. A. Gonçalves, J. Bertrand, R. Ke, E. Comets, X. de Lamballerie, D. Malvy, A. Pizzorno, O. Terrier, M. Rosa
695 Calatrava, F. Mentré, P. Smith, A. S. Perelson, J. Guedj, Timing of Antiviral Treatment Initiation is Critical to
696 Reduce SARS-CoV-2 Viral Load. *CPT Pharmacometrics Syst Pharmacol* **9**, 509–514 (2020).
- 697 22. S. Iwanami, K. Ejima, K. Su Kim, K. Noshita, Y. Fujita, T. Miyazaki, S. Kohno, Y. Miyazaki, S. Morimoto,
698 S. Nakaoka, Y. Koizumi, Y. Asai, K. Aihara, K. Watashi, R. N. Thompson, K. Shibuya, K. Fujiu, A. S. Perelson,
699 S. Iwami, T. Wakita, Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in
700 randomized controlled trials: A modeling study. *PLoS Med* **18**, 25 (2021).

- 701 23. A. Goyal, E. F. Cardozo-Ojeda, J. T. Schiffer, Potency and timing of antiviral therapy as determinants of
702 duration of SARS-CoV-2 shedding and intensity of inflammatory response. *Sci Adv* **6** (2020),
703 doi:10.1126/sciadv.abc7112.
- 704 24. V. Fumagalli, P. Di Lucia, M. Ravà, D. Marotta, E. Bono, S. Grassi, L. Donnici, R. Cannalire, I. Stefanelli, A.
705 Ferraro, F. Esposito, E. Pariani, D. Inverso, C. Montesano, S. Delbue, S. Perlman, E. Tramontano, R. De
706 Francesco, V. Summa, L. G. Guidotti, M. Iannacone, Nirmatrelvir treatment of SARS-CoV-2-infected mice blunts
707 antiviral adaptive immune responses. *EMBO Mol Med* **15**, e17580 (2023).
- 708 25. A. S. Perelson, R. M. Ribeiro, T. Phan, An explanation for SARS-CoV-2 rebound after Paxlovid treatment.
709 *medRxiv* (2023), doi:10.1101/2023.05.30.23290747.
- 710 26. K. Owens, S. Esmaili-Wellman, J. T. Schiffer, Heterogeneous SARS-CoV-2 kinetics due to variable timing
711 and intensity of immune responses. *medRxiv* (2023), doi:10.1101/2023.08.20.23294350.
- 712 27. S. Galmiche, T. Cortier, T. Charmet, L. Schaeffer, O. Chény, C. Von Platen, A. Lévy, S. Martin, F. Omar, C.
713 David, A. Mailles, F. Carrat, S. Cauchemez, A. Fontanet, SARS-CoV-2 incubation period across variants of
714 concern, individual factors, and circumstances of infection in France: a case series analysis from the ComCor
715 study. *Lancet Microbe* **4**, E409–E417 (2023).
- 716 28. C. L. Finch, J. Dyllal, S. Xu, E. A. Nelson, E. Postnikova, J. Y. Liang, H. Zhou, L. E. DeWald, C. J. Thomas,
717 A. Wang, X. Xu, E. Hughes, P. J. Morris, J. C. Mirsalis, L. H. Nguyen, M. P. Arolfo, B. Koci, M. R. Holbrook, L.
718 E. Hensley, P. B. Jahrling, C. Schmaljohn, L. M. Johansen, G. G. Olinger, J. T. Schiffer, J. M. White,
719 Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally
720 Available Approved Drugs against Ebola Virus In Vivo. *Microorganisms* **9**, 566 (2021).
- 721 29. B. T. Mayer, A. C. deCamp, Y. Huang, J. T. Schiffer, R. Gottardo, P. B. Gilbert, D. B. Reeves, Optimizing
722 clinical dosing of combination broadly neutralizing antibodies for HIV prevention. *PLoS Comput Biol* **18** (2022),
723 doi:10.1371/JOURNAL.PCBI.1010003.
- 724 30. A. S. Anderson, P. Caubel, J. M. Rusnak, Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19. *New*
725 *England Journal of Medicine* **387**, 1047–1049 (2022).
- 726 31. G. E. Edelstein, J. Boucau, R. B. Uddin, C. B. Marino, M. Y. Liew BA, M. Barry, M. C. Choudhary, R. F.
727 Gilbert, Z. Reynolds MPH, Y. Li, D. Tien BSA, S. B. Sagar, T. D. Vyas BS, Y. Kawano, J. A. Sparks MMsc, Z.
728 Wallace, J. M. Vyas, J. E. Lemieux, J. Z. Li, M. J. Siedner, SARS-CoV-2 virologic rebound with nirmatrelvir-
729 ritonavir therapy. , doi:10.1101/2023.06.23.23288598.
- 730 32. J. T. Schiffer, D. A. Swan, L. Corey, A. Wald, Rapid viral expansion and short drug half-life explain the
731 incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents. *Antimicrob Agents*
732 *Chemother* **57**, 5820–5829 (2013).
- 733 33. D. B. Reeves, Y. Huang, E. R. Duke, B. T. Mayer, E. Fabian Cardozo-Ojeda, F. A. Boshier, D. A. Swan, M.
734 Rolland, M. L. Robb, J. R. Mascola, M. S. Cohen, L. Corey, P. B. Gilbert, J. T. Schiffer, Mathematical modeling
735 to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials. *PLoS Comput Biol*
736 **16** (2020), doi:10.1371/JOURNAL.PCBI.1007626.
- 737 34. J. T. Schiffer, D. A. Swan, A. Magaret, L. Corey, A. Wald, J. Ossid, H. Ruebsamen-Schaeff, S. Stoelben, B.
738 Timmler, H. Zimmermann, M. R. Melhem, S. A. Van Wart, C. M. Rubino, A. Birkmann, Mathematical modeling
739 of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes. *Sci Transl Med* **8** (2016),
740 doi:10.1126/SCITRANSLMED.AAD6654/SUPPL_FILE/AAD6654_VIDEO_S4.MOV.
- 741 35. S. R. Greenfield, H. Eng, Q. Yang, C. Guo, L. Byrnes, A. Dantonio, G. West, L. Di, A. S. Kalgutkar, Species
742 differences in plasma protein binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main
743 protease inhibitor nirmatrelvir. *Xenobiotica* **53**, 12–24 (2023).
- 744 36. R. K. Hau, S. H. Wright, N. J. Cherrington, PF-07321332 (Nirmatrelvir) does not interact with human ENT1
745 or ENT2: Implications for COVID-19 patients. *Clin Transl Sci* **15**, 1599–1605 (2022).
- 746 37. G. E. Edelstein, J. Boucau, R. Uddin, C. Marino, M. Y. Liew, M. Barry, M. C. Choudhary, R. F. Gilbert, Z.
747 Reynolds, Y. Li, D. Tien, S. Sagar, T. D. Vyas, Y. Kawano, J. A. Sparks, S. P. Hammond, Z. Wallace, J. M. Vyas,
748 A. K. Barczak, J. E. Lemieux, J. Z. Li, M. J. Siedner, SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir
749 therapy. *medRxiv* , 2023.06.23.23288598 (2023).
- 750 38. C. K. H. Wong, K. T. K. Lau, I. C. H. Au, E. H. Y. Lau, L. L. M. Poon, I. F. N. Hung, B. J. Cowling, G. M.
751 Leung, Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a
752 population-wide retrospective cohort study. *Lancet Infect Dis* **23**, 683–695 (2023).
- 753 39. J. A. Pandit, J. M. Radin, D. C. Chiang, E. G. Spencer, J. B. Pawelek, M. Diwan, L. Roumani, M. J. Mina,
754 The Coronavirus Disease 2019 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom
755 Rebound Differences in Participants Treated With Nirmatrelvir Plus Ritonavir Versus Untreated Controls. *Clin*
756 *Infect Dis* **77** (2023), doi:10.1093/CID/CIAD102.
- 757 40. N. S. Zuckerman, E. Bucris, D. Keidar-Friedman, M. Amsalem, T. Brosh-Nissimov, Nirmatrelvir resistance-
758 de novo E166V/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir/ritonavir
759 monotherapy leading to clinical and virological treatment failure—a case report. , doi:10.1093/cid/ciad494.
- 760 41. A. Jayk Bernal, M. M. Gomes da Silva, D. B. Musungaie, E. Kovalchuk, A. Gonzalez, V. Delos Reyes, A.
761 Martín-Quirós, Y. Caraco, A. Williams-Diaz, M. L. Brown, J. Du, A. Pedley, C. Assaid, J. Strizki, J. A. Grobler,

762 H. H. Shamsuddin, R. Tipping, H. Wan, A. Paschke, J. R. Butterson, M. G. Johnson, C. De Anda, Molnupiravir
763 for Oral Treatment of Covid-19 in Nonhospitalized Patients. *New England Journal of Medicine* **386**, 509–520
764 (2022).

765 42. K. M. Elias, S. R. Khan, E. Stadler, T. E. Schlub, D. Cromer, M. N. Polizzotto, S. J. Kent, T. Turner, M. P.
766 Davenport, D. S. Houry, Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in
767 outpatients: A systematic review and meta-analysis. *medRxiv*, 2023.06.18.23291566 (2023).

768 43. R. L. Gottlieb, C. E. Vaca, R. Paredes, J. Mera, B. J. Webb, G. Perez, G. Oguchi, P. Ryan, B. U. Nielsen, M.
769 Brown, A. Hidalgo, Y. Sachdeva, S. Mittal, O. Osiyemi, J. Skarbinski, K. Juneja, R. H. Hyland, A. Osinusi, S.
770 Chen, G. Camus, M. Abdelghany, S. Davies, N. Behenna-Renton, F. Duff, F. M. Marty, M. J. Katz, A. A. Ginde,
771 S. M. Brown, J. T. Schiffer, J. A. Hill, Early Remdesivir to Prevent Progression to Severe Covid-19 in
772 Outpatients. *New England Journal of Medicine* **386**, 305–315 (2022).

773 44. A. F. Carlin, A. E. Clark, A. Chaillon, A. F. Garretson, W. Bray, M. Porrachia, A. L. T. Santos, T. M. Rana,
774 D. M. Smith, Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After
775 Nirmatrelvir/Ritonavir Treatment. *Clin Infect Dis* **76**, E530–E532 (2023).

776 45. B. P. Epling, J. M. Rocco, K. L. Boswell, E. Laidlaw, F. Galindo, A. Kellogg, S. Das, A. Roder, E. Ghedin, A.
777 Kreitman, R. L. Dewar, S. E. M. Kelly, H. Kalish, T. Rehman, J. Highbarger, A. Rupert, G. Kocher, M. R.
778 Holbrook, A. Lisco, M. Manion, R. A. Koup, I. Sereti, Clinical, Virologic, and Immunologic Evaluation of
779 Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment. *Clin Infect Dis*
780 **76**, 573–581 (2023).

781 46. J. Boucau, R. Uddin, C. Marino, J. Regan, J. P. Flynn, M. C. Choudhary, G. Chen, A. M. Stuckwisch, J.
782 Mathews, M. Y. Liew, A. Singh, Z. Reynolds, S. L. Iyer, G. C. Chamberlin, T. D. Vyas, J. M. Vyas, S. E. Turbett,
783 J. Z. Li, J. E. Lemieux, A. K. Barczak, M. J. Siedner, Characterization of Virologic Rebound Following
784 Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19). *Clin Infect Dis* **76**, E526–E529
785 (2023).

786 47. C. C. Lai, P. R. Hsueh, Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment. *J Med*
787 *Virol* **95** (2023), doi:10.1002/JMV.28430.

788 48. J. A. Hay, S. M. Kissler, J. R. Fauver, C. Mack, C. G. Tai, R. M. Samant, S. Connolly, D. J. Anderson, G.
789 Khullar, M. Mackay, M. Patel, S. Kelly, A. Manhertz, I. Eiter, D. Salgado, T. Baker, B. Howard, J. T. Dudley, C.
790 E. Mason, M. Nair, Y. Huang, J. Difiori, D. D. Ho, N. D. Grubaugh, Y. H. Grad, Quantifying the impact of
791 immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: A retrospective cohort study.
792 *Elife* **11** (2022), doi:10.7554/eLife.81849.

793 49. R. S. P. Singh, S. S. Toussi, F. Hackman, P. L. Chan, R. Rao, R. Allen, L. Van Eyck, S. Pawlak, E. P. Kadar,
794 F. Clark, H. Shi, A. S. Anderson, M. Binks, S. Menon, G. Nucci, A. Bergman, Innovative Randomized Phase I
795 Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir. *Clin*
796 *Pharmacol Ther* **112**, 101–111 (2022).

797 50. D. R. Owen, C. M. N. Allerton, A. S. Anderson, L. Aschenbrenner, M. Avery, S. Berritt, B. Boras, R. D.
798 Cardin, A. Carlo, K. J. Coffman, A. Dantonio, L. Di, H. Eng, R. A. Ferre, K. S. Gajiwala, S. A. Gibson, S. E.
799 Greasley, B. L. Hurst, E. P. Kadar, A. S. Kalgutkar, J. C. Lee, J. Lee, W. Liu, S. W. Mason, S. Noell, J. J. Novak,
800 R. S. Obach, K. Ogilvie, N. C. Patel, M. Pettersson, D. K. Rai, M. R. Reese, M. F. Sammons, J. G. Sathish, R. S.
801 P. Singh, C. M. Steppan, A. E. Stewart, J. B. Tuttle, L. Updyke, P. R. Verhoest, L. Wei, Q. Yang, Y. Zhu, An oral
802 SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. *Science* **374**, 1586–1593 (2021).

803 51. J. Wagoner, S. Herring, T.-Y. Hsiang, A. Ianevski, S. B. Biering, S. Xu, M. Hoffmann, S. Pöhlmann, M. Gale,
804 T. Aittokallio, J. T. Schiffer, J. M. White, S. J. Polyak, Combinations of Host- and Virus-Targeting Antiviral
805 Drugs Confer Synergistic Suppression of SARS-CoV-2. *Microbiol Spectr* **10** (2022),
806 doi:10.1128/SPECTRUM.03331-22.

807
808
809
810
811
812
813
814
815
816
817
818
819

820 **Acknowledgments**

821

822 **Funding:**

823 National Institutes of Health (NIH) grants R01AI169427 (JTS)

824 National Institutes of Health (NIH) grants R01AI121129 (JTS)

825 National Institutes of Health (NIH) grants R01AI177512 (JTS, SJP)

826

827 **Author contributions:**

828 Conceptualization: JTS, SE, KO

829 Methodology: JTS, SE, KO

830 Software: SE, KO

831 Investigation: SJP, JW, SE, KO

832 Formal analysis: SE, KO

833 Writing – original draft: JTS, SE

834 Writing – review & editing: JTS, SE, KO, SJP, JW, JMW

835

836 **Competing interests:**

837 Authors declare that they have no competing interests.

838

839 **Data and materials availability:**

840 All code, and materials used in the analysis is available on github at

841 https://github.com/sEsmaeili/Covid_Rebound

842 The data analyzed in this work was previously published by Hay et al. and Schilling et

843 al. and is available on github at [https://github.com/gradlab/SC2-kinetics-immune-](https://github.com/gradlab/SC2-kinetics-immune-history)

844 [history](https://github.com/jwatowatson/PLATCOV-Molnupiravir/tree/V1.0) and <https://github.com/jwatowatson/PLATCOV-Molnupiravir/tree/V1.0>


845

846

847

848 **Figures and Tables**

849



850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865


866

867

Fig. 1. Schematics of the viral dynamic model and nirmatrelvir PK-PD two


compartmental model. (A) The viral dynamic model follows the dynamics of susceptible cells (S), refractory cells (R), eclipse infected cells (I_E), productively infected cells (I_P), and virus (V) and includes the early and late cytolitic T-cell immune responses with rates γ and $m(t)$. ρ is the infection rate, ϕ is the rate of reversion of refractory cells to susceptible cells. Infected cells produce viruses at the rate β , and the free viruses are cleared at the rate γ . **(B)** Two-compartmental PK model with oral administration of the drug which models the amounts of the drug in gut tissue (A_{GI}), plasma (A_P), and the tissue (A_L). K_a is the rate of absorption of the drug from gut to plasma. K_{PL} and K_{LP} are the rates of transfer of the drug from plasma to the tissue and back, and K_{CL} is the rate at which the drug clears from the body. V is the estimated plasma volume and C_P is the drug concentration in plasma. $\epsilon(C_P)$ is the drug efficacy that blocks viral production and is calculated using the Hill equation: _____

where E_{max} is the maximum efficacy, n is the Hill coefficient, IC_{50} is the concentration of drug *in vitro* at which viral replication rate is reduced by 50%, prf is the potency reduction factor translating the *in vitro* potency to *in vivo* potency.



868
 869 **Fig. 2. Lower *in vivo* potency of nirmatrelvir relative to *in vitro* potency in EPIC-**
 870 **HR. (A-B)** mean (blue), individual (gray), and ranges (labeled dashed lines) of
 871 \log_{10} viral load drop from the baseline of individuals randomly selected from
 872 the NBA cohort treated with (A) placebo or (B) five days of nirmatrelvir /
 873 ritonavir 300 mg twice daily. The red dots were obtained by digitizing Fig 3a of
 874 Hammond et al.(1) and model fit was noted by closeness of blue lines to the red
 875 dots. (C) R^2 of the fit of the 10 model simulations per prf to the viral load drop
 876 data in light blue and their mean in dark blue. The best model fit was at a
 877 potency reduction factor of 61. The horizontal boxplot in the lower panel shows
 878 the distribution of prf values at which R^2 is maximum (mean = 61.8, median
 879 =61, sd=3.5). (D) Drug efficacy when prf=61. Average efficacy was 82% over
 880 the 5-day interval, with notable drops in antiviral efficacy at drug troughs. (E)
 881 Average drug efficacy when prf = 1 vs prf = 61. The drug with no potency
 882 reduction has nearly perfect efficacy (average efficacy of 99.99%) over 5 days
 883 and has a prolonged post-treatment effect. (F) mean \log_{10} viral load drop from
 884 baseline of the control arm, treatment arm with prf=61, and treatment arm with
 885 prf=1.
 886

887



888

889

890

891

892

893

894

895

896

897

898

899

900

901

902


903

904

905

906


Fig. 3. Lower *in vivo* potency of nirmatrelvir relative to *in vitro* potency in PLATCOV. (A-B) mean (blue), individual (gray), and ranges (labeled dashed lines) of log₁₀ viral load drop from the baseline of individuals randomly selected from the NBA cohort treated with (A) placebo or (B) five days of nirmatrelvir / ritonavir 300 mg twice daily. The empty and filled red circles are individual and mean viral load drop from baseline calculated from viral load data published by Schilling et al.(5). Model fit was noted by closeness of blue lines to the filled red dots. (C) R² of the fit of the 10 model simulations per prf to the viral load drop data in light blue and their mean in dark blue. The best model fit was at a potency reduction factor of 37. The horizontal boxplot in the lower panel shows the distribution of prf values at which R² is maximum (mean = 36.6, median =37, sd=2.15). (D-E) distribution of log₁₀ viral load drop from baseline of simulated cohort and the 144 individuals in PLATCOV control arm (D) and treatment arm (E). Adjusted p-values (q-values) were calculated using Benjamini-Hochberg method and represent dissimilarity between observed and simulated distributions.



907
 908
 909
 910
 911
 912
 913
 914
 915
 916
 917
 918
 919
 920

Fig. 4. Increasing nirmatrelvir dose lowers short term viral load but increases probability of viral rebound. In all scenarios, simulated treatment starts within the first 3 days post-symptoms. **(A)** log₁₀ viral load at days 2, 5, and 10 after the treatment start day with different doses. p-values were obtained by performing Mann-Whitney U-test between the 300 mg group and the others, and only p-values <math>< 0.01</math> are shown. Viral loads were only reduced by higher doses at days 2 and 5, but not day 10. **(B)** The probability of rebound for different doses. The error bars on each column are 95% confidence intervals. **(C)** Examples of viral load trajectories assuming different doses on 4 modeled individuals with equivalent timing of therapy and untreated viral kinetics.

921



922

923

924

925

926

927

928

929

930

931

932

933

934

Fig. 5. Early timing of therapy initiation is a key risk factor for viral rebound. In all simulations, the dose was 300 mg twice daily for five days. **(A)** log₁₀ viral load at days 2, 5, and 10 after the treatment start day with different treatment durations. p-values were obtained by performing Mann-Whitney U-test. At day 10, the treatment group had higher viral loads compared to placebo due to viral rebound in the PEP and early treatment simulations, despite lowering viral loads significantly at days 2 and 5. **(B)** The probability of rebound for different treatment timing. The error bars on each column are 95% confidence interval **(C)** Samples of viral load trajectories assuming different treatment timing on 4 modeled individuals with equivalent untreated viral kinetics.





Fig. 6. Prolonging treatment duration limits rebound probability. In all simulations, treatment starts within the first 3 days post-symptoms and the dose was 300 mg twice daily. **(A)** log₁₀ viral load at days 2, 5, and 10 after the treatment start day with different treatment durations. p-values were obtained by performing Mann-Whitney U-test and only values <0.01 are shown. At day 10, the control group had equivalent viral loads to 5 days of treatment while 10 days of treatment significantly lowered viral load. **(B)** The probability of rebound for different treatment durations. The error bars on each column are 95% confidence interval. **(C)** Samples of viral load trajectories assuming different treatment durations on 4 modeled individuals with equivalent timing of therapy and untreated viral kinetics. Prolonging therapy often avoids rebound.


935
 936
 937
 938
 939
 940
 941
 942
 943
 944
 945
 946
 947



948
949

950 **Fig. 7. Post-exposure prophylaxis requires more prolonged therapy than early**
951 **symptomatic therapy to avoid viral rebound. (A) probability of rebound and**
952 **(B) viral load at the end of the treatment as a function of treatment timing and**
953 **duration.**

954



955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971

Fig. 8. Early therapy preserves susceptible cells, limits refractory cells, does not eliminate all infected cells, and delays innate immune responses.

Simulations are performed using time since infection as a variable rather than based on symptoms as in prior figures to eliminate the confounding impact of variable incubation period. **(A)** The top row shows the viral load of all individuals (in grey) and the average viral load (in blue). The middle row shows a less substantial depletion of susceptible cells (S), and lower generation of refractory cells (R) with earlier therapy. The bottom row shows the rate of production of refractory cells likely representing innate immune responses per day with biphasic, lower peak responses noted with early therapy and to a lesser extent in day 4 treated individuals. **(B)** Ratios of susceptible (S) to refractory cells (R) at the end of the 5-day treatment for different timings of treatment. **(C)** Per cell production rate of refractory cells at the end of the 5-day treatment for different timings of treatment.